{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:11:56Z","timestamp":1784362316583,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: The role of surgery and non-surgical locoregional treatments (LRT) such as radiation therapy (RT) and local ablation techniques in patients with metastatic gastrointestinal stromal tumor (GIST) is unclear. This study examines LRT practice patterns in metastatic GIST and their clinical outcomes in British Columbia (BC). Methods: Patients diagnosed with either recurrent or de novo metastatic GIST from January 2008 to December 2017 were identified. Clinical characteristics and outcomes were analyzed in patients who underwent LRT, including surgical resection of the primary tumor or metastectomy, RT, or other local ablative procedures. Results: 127 patients were identified: 52 (41%) had de novo metastasis and 75 (59%) had recurrent metastasis. Median age was 67 (23\u201390 years), 58.2% were male, primary site was 33.1% stomach, 40.2% small intestine, 11% rectum\/pelvis, and 15.7% others. 37 (29.1%) of patients received palliative surgery, the majority of which had either primary tumor removal only (43.3%) or both primary tumor removal and metastectomy (35.1%). A minority of patients underwent metastectomy only (21.6%). A total of 12 (9.5%) patients received palliative RT to metastatic sites only (58.3%) or primary tumors only (41.7%), mostly for symptomatic control (n = 9). A few patients (n = 3) received local ablation for liver metastatic deposits with 1 patient receiving microwave ablation (MWA) and 2 receiving radiofrequency ablation (RFA). Most patients (n = 120, 94.5%) received some type of systemic treatment. It is notable that prolonged progression free survival (PFS) was observed for the majority of patients who underwent surgery in the metastatic setting with a median PFS of 20.5 (95% confidence interval (CI): 14.29\u201340.74) months. In addition, significantly higher median overall survival (mOS) was observed in patients who underwent surgery (97.15 months; 95% CI: 77.7-not reached) and LRT (78.98 months; 95% CI: 65.58-not reached) versus no surgery (45.37 months; 95% CI: 38.7\u201364.69) and no LRT (45.27 months; 95% CI: 33.25\u201358.66). Almost all patients (8 out of 9) achieved symptomatic improvement after palliative RT. All 3 patients achieved partial response and 2 out of 3 patients had relatively durable responses of 1 year or more after local ablation. Discussion: This study is among the first to systematically examine the use of various LRT in metastatic GIST management. Integration of LRT with systemic treatments may potentially provide promising durable response and prolonged survival for highly selected metastatic GIST patients with low volume disease, limited progression and otherwise well controlled on systemic treatments. These observations, consistent with others, add to the growing evidence that supports the judicious use of LRT in combination with systemic treatments to further optimize the care of metastatic GIST patients.<\/jats:p>","DOI":"10.3390\/cancers14061477","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T03:06:10Z","timestamp":1647313570000},"page":"1477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-8521","authenticated-orcid":false,"given":"Tiffany","family":"Patterson","sequence":"first","affiliation":[{"name":"Clinical Trials, BC Cancer\u2014Vancouver Island Center, Victoria, BC V8R 6V5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Debruyns","sequence":"additional","affiliation":[{"name":"Department of Medicine, Island Medical Program, University of British Columbia, Victoria, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of British Columbia, BC Cancer\u2014Vancouver Center, Vancouver, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-0691","authenticated-orcid":false,"given":"Jason","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of British Columbia, BC Cancer\u2014Vancouver Island Center, Victoria, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Pollock","sequence":"additional","affiliation":[{"name":"Clinical Trials, BC Cancer\u2014Vancouver Island Center, Victoria, BC V8R 6V5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Holloway","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of British Columbia, BC Cancer\u2014Vancouver Island Center, Victoria, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline T.","family":"Truong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of British Columbia, BC Cancer\u2014Vancouver Island Center, Victoria, BC V1Y 1T3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7333-8198","authenticated-orcid":false,"given":"Xiaolan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V1Y 1T3, Canada"},{"name":"Department of Medical Oncology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-013-2135-8","article-title":"Long-term efficacy of imatinib for treatment of metastatic GIST","volume":"72","author":"Patel","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): A multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","article-title":"Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 \u2018CaboGIST\u2019","volume":"134","author":"Mir","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/CCO.0000000000000642","article-title":"New drugs in gastrointestinal stromal tumors","volume":"32","author":"Moura","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","article-title":"Secondary KIT mutations: The GIST of drug resistance and sensitivity","volume":"120","author":"Napolitano","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.20013","article-title":"Local Surgical, Ablative, and Radiation Treatment of Metastases","volume":"59","author":"Timmerman","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1200\/EDBK_157450","article-title":"Local Ablative Therapies to Metastatic Soft Tissue Sarcoma","volume":"35","author":"Gronchi","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2018.02.017","article-title":"Interventional radiology: Role in the treatment of sarcomas","volume":"94","author":"Tselikas","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-020-00936-5","article-title":"The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma","volume":"22","author":"Farooqi","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1245\/s10434-014-4360-8","article-title":"Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)","volume":"22","author":"Calabuig","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.soc.2005.12.003","article-title":"Surgical Management of Distant Metastases","volume":"15","author":"Ollila","year":"2006","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10985-007-9065-x","article-title":"Generalized linear mixed models: A review and some extensions","volume":"13","author":"Dean","year":"2007","journal-title":"Lifetime Data Anal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejca.2014.03.280","article-title":"Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China","volume":"50","author":"Du","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","article-title":"Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014Analysis of prognostic factors (EORTC-STBSG collaborative study)","volume":"40","author":"Bauer","year":"2014","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10147-007-0657-y","article-title":"Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy","volume":"12","author":"Hasegawa","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.sla.0000242710.36384.1b","article-title":"Surgery of Residual Disease Following Molecular-targeted Therapy with Imatinib Mesylate in Advanced\/Metastatic GIST","volume":"245","author":"Gronchi","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","article-title":"Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor","volume":"245","author":"DeMatteo","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/SLA.0000000000002281","article-title":"Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A 2-institutional Analysis","volume":"268","author":"Fairweather","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00595-009-4171-x","article-title":"Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors","volume":"40","author":"Xia","year":"2010","journal-title":"Surg. Today"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Patterson, T., Chai, J., Li, H., de Bruyns, A., Cleversey, C., Lee, C.-H., Yip, S., Simmons, C., Hart, J., and Pollock, P. (2021). Utilization of Mutational Analysis (MA) in Gastrointestinal Stromal Tumor (GIST) Management in British Columbia (BC) between January 2008 to December 2017: A Retrospective Population-Based Study. J. Gastrointest. Cancer, 1\u20139.","DOI":"10.1007\/s12029-021-00682-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1748-717X-8-207","article-title":"Intensity modulated radiotherapy of upper abdominal malignancies: Dosimetric comparison with 3D conformal radiotherapy and acute toxicity","volume":"8","author":"Nour","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000106041","article-title":"Upper Abdominal Malignancies: Intensity-Modulated Radiation Therapy","volume":"40","author":"Taremi","year":"2007","journal-title":"Front. Radiat. Ther. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.radonc.2015.07.025","article-title":"Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study","volume":"116","author":"Joensuu","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1748-717X-8-274","article-title":"External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors","volume":"8","author":"Cuaron","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/030089160909500217","article-title":"Molecularly Targeted Therapy and Radiotherapy in the Management of Localized Gastrointestinal Stromal Tumor (GIST) of the Rectum: A Case Report","volume":"95","author":"Ciresa","year":"2009","journal-title":"Tumori J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/CAD.0b013e3280e94982","article-title":"Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate","volume":"18","author":"Boruban","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4081\/rt.2011.e49","article-title":"Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor","volume":"3","author":"Lolli","year":"2011","journal-title":"Rare Tumors"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1200\/jco.2004.22.90140.9024","article-title":"Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM)","volume":"22","author":"Dileo","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejso.2009.12.005","article-title":"Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma","volume":"36","author":"Jones","year":"2010","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jvir.2015.09.002","article-title":"Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal Stromal Tumor","volume":"26","author":"Jung","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/cncr.22336","article-title":"Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: Response, survival, and prognostic factors","volume":"107","author":"Kobayashi","year":"2006","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.3748\/wjg.v18.i42.6134","article-title":"Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases","volume":"18","author":"Cao","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12029-014-9663-2","article-title":"Hepatic Artery Embolization for Liver Metastasis of Gastrointestinal Stromal Tumor following Imatinib and Sunitinib Therapy","volume":"45","author":"Takaki","year":"2014","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/COC.0b013e31819cca35","article-title":"Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors","volume":"32","author":"Kobayashi","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jvir.2014.09.020","article-title":"Radioembolization in Patients with Progressive Gastrointestinal Stromal Tumor Liver Metastases Undergoing Treatment with Tyrosine Kinase Inhibitors","volume":"26","author":"Rathmann","year":"2014","journal-title":"J. Vasc. Interv. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:15Z","timestamp":1760135775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14061477"],"URL":"https:\/\/doi.org\/10.3390\/cancers14061477","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}